- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05657184
Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001
October 10, 2023 updated by: Regend Therapeutics
An Open-labelled Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 Autologous Therapy Product for Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues.
REGEND001 Autologous Therapy Product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment.
In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 Autologous Therapy Product in treatment of IPF.
Different doses of REGEND001 Autologous Therapy Product is evaluated to establish a dose-response relationship and to recommend appropriate dose for subsequent clinical trials.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zuojun Xu, M.D.
- Phone Number: 86-10-69156114
- Email: xuzj@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
-
Guangdong
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, aged between 50 to 75;
- Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathic pulmonary fibrosis 2018 edition;
- Subjects with 30%~79% of the predicted value in diffusing capacity for carbon monoxide (DLCO) and more than 50% of the predicted value in forced vital capacity (FVC) in pulmonary function tests 3 months before screening;
- Subjects with typical High-resolution computed tomography (HR-CT) imaging findings of idiopathic pulmonary fibrosis in the past 12 months;
- Subjects tolerant to bronchofiberscope;
- Subjects fully informed of the purpose, method and possible discomfort of the trial, agreeing to participate in the test, and voluntarily signing the informed consent;
- Subjects with good adherence, willingness to take medication and regular follow-up examinations as required by the protocol ;
- Subjects able to understand and cooperate with the completion of pulmonary function tests.
Exclusion Criteria:
- Subjects who cannot tolerate cell therapy
- Pregnant or lactating women;
- Subjects with syphilis or any of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) positive antibody; Of which stable HBV carriers after drug treatment (DNA titer ≤500 IU/mL or copy number <1000 copies/mL) and cured hepatitis C patients (HCV RNA is negative) can be enrolled;
- Subjects with malignant tumors or a history of malignant tumors;
- Subjects with taking drugs which caused lung fibroblast such as amiodarone in a long term before screening;
- Subjects with infections in lung or other site, including bacterial and viral infections, requiring intravenous treatment before cell transplantation;
- Subjects with a history of invasive or noninvasive mechanical ventilation within 4 weeks;
- Subjects with any of the following lung diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, pneumoconiosis, etc.; lung cancer, bronchiolitis obliterans or other active lung disease; Pneumonia currently or within the last 4 weeks; Pneumonectomy Previously;
- Subjects needing oxygen therapy currently (oxygen therapy time> 15h/d);
- Subjects suffering from serious other systemic diseases, such as myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis, connective tissue disease, etc.;
- Subjects with following results : leukopenia (leukopenia < 4×10^9/L) or agranulocytosis (leukocyte < 1.5×10^9/L or neutrophils < 0.5×10^9/L) of any cause; Blood creatinine > 2.5 times the upper limit of normal; Alanine transaminase (ALT) and Aspartate transaminase (AST) > 2.5 times the upper limit of normal values in the laboratory tests.
- Subjects with a history of mental illness or suicide risk, epilepsy or other central nervous system disorders
- Subjects with severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or atrioventricular block of degree II or above, shown by 12-lead Electrocardiogram (ECG);
- Subjects with a history of abusing alcohol and illicit drug;
- Subjects who are allergic to cattle products;
- Subjects who participated in other clinical trials in the past 3 months;
- Subjects with poor compliance and difficult to complete the investigation;
- Investigators, employees of research centers or family members of them (none of whom are suitable to participate in the trial to ensure the objectivity of the research);
- Subjects who had an acute exacerbation of IPF or hospitalized for other respiratory diseases 3 or more times in the past 1 year;
- Subjects who take nintedanib for medication within 1 month, or plan to continue taking nintedanib for medication;
- Subjects with other acquired or congenital immunodeficiency disorders, or with a history of organ transplantation or cell transplant therapy;
- Subjects whose expected survival may be less than one year judged by the investigator;
- Male participants of childbearing potential and female participants within childbearing age were reluctant to use effective contraception from the time of signing the informed consent to 6 months after cell therapy;
- Subjects assessed as inappropriate to participate in this clinical trial by investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: REGEND001 autologous bronchial basal cells
Transplantation of autologous bronchial basal cells
|
Transplantation of REGEND001 Autologous Therapy Product for dosage re-escalation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of the cell therapy-related adverse events (AEs)
Time Frame: Within 24 weeks after treatment
|
Dose escalation is based on incidence of cell therapy-related AEs.
Severity of cell therapy-related adverse events (AEs) is evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).
|
Within 24 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of complication related to bronchoscopy
Time Frame: Within 24 weeks after treatment
|
REGEND001 Autologous Therapy Product is given to subjects by bronchoscopy.
Thus, incidence of complication related to bronchoscopy is adapted to assess the safety of the products.
|
Within 24 weeks after treatment
|
Change of lung diffusing capacity for single-breath carbon monoxide (DLCO-sb) from baseline
Time Frame: 4, 12, and 24 weeks after treatment
|
DLCO-sb is measured by the single-breath method.
It is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
|
4, 12, and 24 weeks after treatment
|
Change of forced vital capacity (FVC) from baseline
Time Frame: 4 weeks after treatment, 12 weeks after treatment and 24 weeks after treatment
|
FVC indicates the volume of air that can forcibly be blown out after full inspiration.
|
4 weeks after treatment, 12 weeks after treatment and 24 weeks after treatment
|
Change of the ratio of diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
Time Frame: 4 weeks after treatment, 12 weeks after treatment and 24 weeks after treatment
|
The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs.
It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) should be considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume.
|
4 weeks after treatment, 12 weeks after treatment and 24 weeks after treatment
|
Change of 6-minute-walk test (6MWT) from baseline
Time Frame: 4 weeks after treatment, 12 weeks after treatment, and 24 weeks after treatment
|
The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.
|
4 weeks after treatment, 12 weeks after treatment, and 24 weeks after treatment
|
Change of St. George's respiratory questionnaire (SGRQ) scale from baseline
Time Frame: 4 weeks after treatment, 12 weeks after treatment, and 24 weeks after treatment
|
Quality of life was assessed by St. George's respiratory questionnaire (SGRQ) scale.
Total score, ranged from 0 to 100, is the sum of points from all items.
A higher value represents a worse outcome.
|
4 weeks after treatment, 12 weeks after treatment, and 24 weeks after treatment
|
Change of imaging of lung by high resolution computed tomography (HR-CT)
Time Frame: 24 weeks after treatment
|
Images of lung will be analyzed to indicate the newly-derived pulmonary structure.
|
24 weeks after treatment
|
Idiopathic pulmonary fibrosis (IPF) exacerbation events
Time Frame: Within 24 weeks after treatment
|
Frequency and severity of IPF exacerbation events will be evaluated.
|
Within 24 weeks after treatment
|
Blood routine
Time Frame: Within 24 weeks after treatment.
|
Number of cases of participants with abnormal laboratory test results.
|
Within 24 weeks after treatment.
|
Urine routine
Time Frame: Within 24 weeks after treatment.
|
Number of cases of participants with abnormal laboratory test results.
|
Within 24 weeks after treatment.
|
Blood biochemistry
Time Frame: Within 24 weeks after treatment
|
Number of cases of participants with abnormal laboratory test results.
|
Within 24 weeks after treatment
|
12-lead Electrocardiogram (ECG)
Time Frame: Within 24 weeks after treatment
|
Number of cases of participants with abnormal 12-lead Electrocardiogram (ECG)
|
Within 24 weeks after treatment
|
Carcinoembryonic antigen (CEA)
Time Frame: Baseline, 12 weeks after treatment, 24 weeks after treatment
|
CEA is a tumor marker used for early diagnosis of lung cancer.
|
Baseline, 12 weeks after treatment, 24 weeks after treatment
|
Neuron-specific enolase (NSE)
Time Frame: Baseline, 12 weeks after treatment, 24 weeks after treatment
|
NSE is a tumor marker significantly elevated in small cell lung cancer.
|
Baseline, 12 weeks after treatment, 24 weeks after treatment
|
Cytokeratin-19-fragment (CYFRA21-1)
Time Frame: Baseline, 12 weeks after treatment, 24 weeks after treatment
|
CYFRA21-1 is a tumor marker which has important value for the pathological classification and prognosis evaluation of lung cancer.
|
Baseline, 12 weeks after treatment, 24 weeks after treatment
|
Squamous cell carcinoma antigen (SCC)
Time Frame: Baseline, 12 weeks after treatment, 24 weeks after treatment
|
SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety.
|
Baseline, 12 weeks after treatment, 24 weeks after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2021
Primary Completion (Actual)
June 9, 2023
Study Completion (Actual)
June 9, 2023
Study Registration Dates
First Submitted
November 15, 2022
First Submitted That Met QC Criteria
December 19, 2022
First Posted (Actual)
December 20, 2022
Study Record Updates
Last Update Posted (Actual)
October 12, 2023
Last Update Submitted That Met QC Criteria
October 10, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XHYX-IND-IPF-P1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on REGEND001 Autologous Therapy Product
-
Regend TherapeuticsShanghai Zhongshan Hospital; Southwest Hospital, China; Ruijin Hospital; The First... and other collaboratorsRecruitingChronic Obstructive Pulmonary DiseaseChina
-
John ListerMiltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed LymphomaUnited States
-
Nantes University HospitalUnknown
-
Eureka Therapeutics Inc.TerminatedHepatocellular Carcinoma | Liver Neoplasm | Liver Cancer | Metastatic Liver CancerUnited States
-
Eureka Therapeutics Inc.TerminatedHepatocellular Carcinoma | Liver Neoplasm | Liver Cancer | Metastatic Liver CancerUnited States
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
Leland MethenyNot yet recruitingLymphoproliferative Disorders | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Allogeneic Stem Cell Transplant Candidate | Acute Myeloid/Lymphoblastic LeukemiaUnited States
-
Dr. Grant M. PagdinRecruitingOsteoarthritisCanada
-
University of EdinburghBritish Heart FoundationSuspendedMyocardial Infarction | InflammationUnited Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted